Kidney disease (autosomal dominant polycystic) - tolvaptan [ID652]: committee papers
01 - Pre-Meeting Briefing prepared by NICE
02 - Submission from the technology company - Otsuka
03 - Patient Access Scheme submission from the company
04 - NICE request to the manufacturer for clarification on their submission
05 - Manufacturer clarification response
06 - Consultee submission - PKD Charity
07 - Consultee submission - Renal Association
08 - Consultee submission - Royal College of Pathologists
09 - Clinical expert personal perspective - Ong
10 - Clinical expert personal perspective - Hendry
11 - Patient expert personal perspective - Goren
12 - Patient expert personal perspective - Williams
13 - Evidence Review Group report prepared by Kleijnen Systematic Reviews
14 - Evidence Review Group addendum report prepared by Kleijnen Systematic Reviews
15 - Manufacturer factual accuracy check of Evidence Review Group report
16 - Evidence Review Group erratum report prepared by Kleijnen Systematic Reviews
Kidney disease (autosomal dominant polycystic) - tolvaptan [ID652]: committee papers
05 June 2015 (6.6 Mb 47 sec) |
This page was last updated: 03 June 2015